David D Berg, Kieran F Docherty, Naveed Sattar, Petr Jarolim, Paul Welsh, Pardeep S Jhund, Inder S Anand, Vijay Chopra, Rudolf A de Boer, Mikhail N Kosiborod, Jose C Nicolau, Eileen O'Meara, Morten Schou, Ann Hammarstedt, Anna-Maria Langkilde, Daniel Lindholm, Mikaela Sjöstrand, John J V McMurray, Marc S Sabatine, David A Morrow
BACKGROUND: Circulating high-sensitivity cardiac troponin T (hsTnT) predominantly reflects myocardial injury, and higher levels are associated with a higher risk of worsening heart failure and death in patients with heart failure with reduced ejection fraction. Less is known about the prognostic significance of changes in hsTnT over time, the effects of dapagliflozin on clinical outcomes in relation to baseline hsTnT levels, and the effect of dapagliflozin on hsTnT levels. METHODS: DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) was a randomized, double-blind, placebo-controlled trial of dapagliflozin (10 mg daily) in patients with New York Heart Association class II to IV symptoms and left ventricular ejection fraction ≤40% (median follow-up, 18...
January 18, 2022: Circulation